课题基金基金详情
基于COX/LTs/NF-κB通路介导的胃粘膜损伤探索药对三棱—莪术联合阿司匹林治疗糖尿病肾病的合理性与分子机制研究
结题报告
批准号:
82004357
项目类别:
青年科学基金项目
资助金额:
24.0 万元
负责人:
武曦蔼
依托单位:
学科分类:
中医内科学
结题年份:
2023
批准年份:
2020
项目状态:
已结题
项目参与者:
武曦蔼
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
中医治疗糖尿病肾病(DN)优势特色显著。课题组前期研究证实肾络瘀阻是DN病机演变的关键环节。三棱—莪术作为活血消癥代表药对,广泛用于DN临床。作为心血管事件高危人群,DN患者常使用阿司匹林(ASA)进行冠心病预防。二者联用是否加重胃粘膜损伤导致消化道出血风险增加这一关键临床问题亟须阐释。根据文献报道,COX/LTs/NF-κB信号通路在ASA导致的胃黏膜损伤中发挥重要调节作用;三棱-莪术可通过调控NF-κB通路减轻胃黏膜病变。据此申请者提出三棱—莪术通过调控COX/LTs/NF-κB通路,在治疗DN肾纤维化的同时,改善ASA诱导胃黏膜损伤的假说。本研究应用免疫组化、qPCR等技术,通过体内、外研究明确三棱—莪术对ASA诱导DN胃黏膜损伤的干预作用,以COX/LTs/NF-κB通路为核心开展其作用靶标的深入研究,阐明二者联合用药减轻胃粘膜损伤的分子机制,为临床合理用药提供科学依据。
英文摘要
Traditional Chinese medicine has certain advantages in treatment of diabetic nephropathy (DN). Our previous studies confirmed that kidney stasis is the key link in the pathogenesis of DN. Rhizome Sparganii & Rhizoma Curcumae is a representative drug pair for promoting blood circulation and eliminating disease, and is widely used in clinic treatment of DN. As a high-risk group of cardiovascular events, DN patients often use aspirin (ASA) for coronary heart disease prevention. Whether the combination of the two will aggravate gastric mucosal damage leads to increased risk of gastrointestinal bleeding is a critical clinical issue that needs to be clarified. According to the reports, the COX / LTs / NF-κB signaling pathway plays an important regulatory role in the gastric mucosal damage caused by ASA; Rhizome Sparganii & Rhizoma Curcumae can relieve gastric mucosal injury by regulating the NF-κB pathway. Based on this, it is proposes that the Rhizome Sparganii & Rhizoma Curcumae by regulating the COX / LTs / NF-κB pathway, while treating DN renal fibrosis, improves the hypothesis that ASA induces gastric mucosal damage. In this study, STZ + unilateral nephrectomy DN rat model was used, with immunohistochemistry, qPCR and other techniques, were used to determine the intervention effect of Rhizome Sparganii & Rhizoma Curcumae on ASA-induced DN gastric mucosal injury through in vivo and in vitro studies. The COX/LTs/NF-κB pathway was used as the core to develop its target Research to clarify the molecular mechanism of the combined use of the two drugs to reduce gastric mucosal damage and provide a scientific basis for the rational use of drugs in the clinic.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:--
发表时间:2022
期刊:中国新药与临床杂志
影响因子:--
作者:李至泓;毕嘉宁;武曦蔼
通讯作者:武曦蔼
DOI:--
发表时间:2023
期刊:中日友好医院学报
影响因子:--
作者:杨景舒;杨猛;李平;赵海玲;孙秋月;武曦蔼;杨鑫;张韫;龚文心;程思益;李忻
通讯作者:李忻
DOI:--
发表时间:2023
期刊:中国医药导报
影响因子:--
作者:毕嘉宁;李至泓;武曦蔼
通讯作者:武曦蔼
国内基金
海外基金